Acura Pharmaceuticals, Inc.  

(Public, NASDAQ:ACUR)   Watch this stock  
Find more results for ACUR
1.29
-0.01 (-0.78%)
Real-time:   2:43PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.26 - 1.30
52 week 1.17 - 3.78
Open 1.26
Vol / Avg. 47,415.00/376,634.00
Mkt cap 63.01M
P/E     -
Div/yield     -
EPS -0.29
Shares 48.85M
Beta 1.63
Inst. own 57%
May 5, 2014
Q1 2014 Acura Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
May 1, 2014
Acura Pharmaceuticals, Inc. Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
Apr 11, 2014
Acura Pharmaceuticals, Inc. Announces Return of Product Rights Conference Call
Mar 11, 2014
Acura Pharmaceuticals, Inc. at ROTH Conference
Mar 4, 2014
Q4 2013 Acura Pharmaceuticals, Inc. Earnings Conference Call
Mar 3, 2014
Q4 2013 Acura Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -9762.86% -11301.63%
Operating margin -9945.71% -11455.28%
EBITD margin - -11346.34%
Return on average assets -54.40% -48.19%
Return on average equity -71.07% -61.03%
Employees 15 -
CDP Score - -

Address

Suite 120, 616 N. North Court
PALATINE, IL 60067
United States - Map
+1-847-7057709 (Phone)
+1-847-7055399 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acura Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. Impede Technology is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. As of December 31. 2012, the Company had seven additional opioid products utilizing Aversion in various stages of development.

Officers and directors

Robert B. Jones President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Peter A. Clemens Chief Financial Officer, Senior Vice President, Secretary
Age: 60
Bio & Compensation  - Reuters
Robert A. Seiser C.P.A. Vice President, Corporate Controller and Treasurer
Age: 49
Bio & Compensation  - Reuters
J. Bradley Rivet Vice President - Marketing
Age: 59
Bio & Compensation  - Reuters
Albert W. Brzeczko Ph.D. Vice President -Technical Affairs
Age: 56
Bio & Compensation  - Reuters
James F. Emigh R.Ph. Vice President - Corporate Development
Age: 57
Bio & Compensation  - Reuters
George K. Ross Independent Director
Age: 71
Bio & Compensation  - Reuters
William G. Skelly Independent Director
Age: 62
Bio & Compensation  - Reuters
Immanuel Thangaraj Independent Director
Age: 42
Bio & Compensation  - Reuters
Bruce F. Wesson Independent Director
Age: 70
Bio & Compensation  - Reuters